
Verastem Oncology Shares Two-Year Follow-Up Data for AVMAPKI+ FAKZYNJA in Recurrent LGSOC at SGO 2026
Verastem Oncology Presents Two-Year Follow-Up Data Highlighting Durable Benefits of AVMAPKI and FAKZYNJA Combination in Recurrent LGSOC Verastem Oncology has announced updated findings from the Phase 2 RAMP 201 clinical trial, showcasing two-year median follow-up data for its combination therapy…











